Overview

a PMS on Safety Profile of Pramipexole in Chinese Parkinson Disease Patients

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, non-interventional, prospective observational study. we collect the safety information of pramipexole over 12w treatment. Parkinson disease patients with different severity who have already used pramipexole could be observed in this study. In the whole observation period, treatment decision was determined by physician and patient completely. The safety endpoint is AE(Adverse Event), SAE(Serious Adverse Event), patient withdraw, laboratory test.
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Pramipexole